Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marie Boyd

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 13, 2012
Inhibition of poly(ADP-Ribose) polymerase enhances the toxicity of 131I-metaiodobenzylguanidine/topotecan combination therapy to cells and xenografts that express the noradrenaline transporterAnthony G McCluskey, Robert J Mairs, Mathias Tesson, et al.
The Analyst|June 27, 2023
Evaluating nanoparticle localisation in glioblastoma multicellular tumour spheroids by surface enhanced Raman scatteringSamantha M McCabe, Gregory Q Wallace, Sian Sloan-Dennison, et al.
The Journal of Biological Chemistry|February 15, 2011
Deletion of the dual specific phosphatase-4 (DUSP-4) gene reveals an essential non-redundant role for MAP kinase phosphatase-2 (MKP-2) in proliferation and cell survivalAhmed Lawan, Sameer Al-Harthi, Laurence Cadalbert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
[131I]meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporterAnthony G McCluskey, Marie Boyd, Susan C Ross, et al.
European Urology|January 22, 2005
Application of targeted radiotherapy/gene therapy to bladder cancer cell linesNatasha E Fullerton, Robert J Mairs, David Kirk, et al.
Radiation Research|January 23, 2013
Gamma irradiation and targeted radionuclides enhance the expression of the noradrenaline transporter transgene controlled by the radio-inducible p21(WAF1/CIP1) promoterAnthony G McCluskey, Robert J Mairs, Annette Sorensen, et al.
The Analyst|June 6, 2024
Live chicken egg embryos as an alternative <i>in vivo</i> tumour model for deep surface enhanced Raman spectroscopySamantha M McCabe, Hannah Gardiner, Calum Mullen, et al.
Cancer Biotherapy & Radiopharmaceuticals|June 29, 2010
Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distributionJohn A Barrett, John L Joyal, Shawn M Hillier, et al.
The Journal of Gene Medicine|August 5, 2004
An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation-mediated bystander effectsMarie Boyd, Robert J Mairs, W Nicol Keith, et al.
The Prostate|December 1, 2020
Determining the prognostic significance of IKKα in prostate cancerMelania Montes, Lewis MacKenzie, Milly J McAllister, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 13, 2012
Inhibition of poly(ADP-Ribose) polymerase enhances the toxicity of 131I-metaiodobenzylguanidine/topotecan combination therapy to cells and xenografts that express the noradrenaline transporterAnthony G McCluskey, Robert J Mairs, Mathias Tesson, et al.
The Analyst|June 27, 2023
Evaluating nanoparticle localisation in glioblastoma multicellular tumour spheroids by surface enhanced Raman scatteringSamantha M McCabe, Gregory Q Wallace, Sian Sloan-Dennison, et al.
The Journal of Biological Chemistry|February 15, 2011
Deletion of the dual specific phosphatase-4 (DUSP-4) gene reveals an essential non-redundant role for MAP kinase phosphatase-2 (MKP-2) in proliferation and cell survivalAhmed Lawan, Sameer Al-Harthi, Laurence Cadalbert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
[131I]meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporterAnthony G McCluskey, Marie Boyd, Susan C Ross, et al.
European Urology|January 22, 2005
Application of targeted radiotherapy/gene therapy to bladder cancer cell linesNatasha E Fullerton, Robert J Mairs, David Kirk, et al.
Radiation Research|January 23, 2013
Gamma irradiation and targeted radionuclides enhance the expression of the noradrenaline transporter transgene controlled by the radio-inducible p21(WAF1/CIP1) promoterAnthony G McCluskey, Robert J Mairs, Annette Sorensen, et al.
The Analyst|June 6, 2024
Live chicken egg embryos as an alternative <i>in vivo</i> tumour model for deep surface enhanced Raman spectroscopySamantha M McCabe, Hannah Gardiner, Calum Mullen, et al.
Cancer Biotherapy & Radiopharmaceuticals|June 29, 2010
Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distributionJohn A Barrett, John L Joyal, Shawn M Hillier, et al.
The Journal of Gene Medicine|August 5, 2004
An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation-mediated bystander effectsMarie Boyd, Robert J Mairs, W Nicol Keith, et al.
The Prostate|December 1, 2020
Determining the prognostic significance of IKKα in prostate cancerMelania Montes, Lewis MacKenzie, Milly J McAllister, et al.
Pageof 4